IRADIMED CORP·4

Jun 4, 4:21 PM ET

Scharen-Guivel Hilda Frederique 4

4 · IRADIMED CORP · Filed Jun 4, 2026

Research Summary

AI-generated summary of this filing

Updated

IRADIMED (IRMD) Director Hilda Scharen-Guivel Sells 3,000 Shares

What Happened
Hilda Frederique Scharen-Guivel, a director of IRADIMED Corp. (IRMD), sold a total of 3,000 shares in two open-market transactions on 2026-06-04. The trades were: 1,766 shares at $95.00 ($167,770) and 1,234 shares at $95.00 ($117,230), for a combined proceeds of $285,000. These were sales (transaction code S), which are often routine liquidity events rather than explicit bullish signals.

Key Details

  • Transaction date and price: 2026-06-04 — 1,766 shares @ $95.00 and 1,234 shares @ $95.00.
  • Total disposed: 3,000 shares for $285,000.
  • Shares owned after transaction: the filing does not list a specific post-transaction total in the data provided here; footnote F2 states the reported beneficial ownership following the transaction consists of shares acquired upon vesting and settlement of restricted stock units (RSUs) granted for director service (acquired in multiple vesting events).
  • Footnotes: F1 confirms the trades executed at $95.00 and offers to provide full transaction details on request; F2 explains the source of the reported beneficial ownership (RSU vesting).
  • Filing timeliness: Reported and filed on 2026-06-04 (no late filing indicated).

Context: These were open-market sales of already-issued shares (not option exercises or gifts). Sales by directors can reflect routine portfolio management, cash needs, or vesting-related liquidity; they are factual disclosures and do not by themselves indicate company outlook.

Insider Transaction Report

Form 4
Period: 2026-06-04
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-06-04$95.00/sh1,766$167,7706,832 total
  • Sale

    Common Stock

    [F1][F2]
    2026-06-04$95.00/sh1,234$117,2305,598 total
Footnotes (2)
  • [F1]This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F2]The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates.
Signature
/s/ Hilda Scharen-Guivel|2026-06-04

Documents

1 file
  • 4
    wk-form4_1780604510.xmlPrimary

    FORM 4